144 related articles for article (PubMed ID: 38018884)
1. Exploration of 3,4-unsubstituted coumarins as thioredoxin reductase 1 inhibitors for cancer therapy.
Nikitjuka A; Ozola M; Jackevica L; Bobrovs R; Žalubovskis R
Org Biomol Chem; 2023 Dec; 21(48):9630-9639. PubMed ID: 38018884
[TBL] [Abstract][Full Text] [Related]
2. Novel electrophilic amides amenable by the Ugi reaction perturb thioredoxin system via thioredoxin reductase 1 (TrxR1) inhibition: Identification of DVD-445 as a new lead compound for anticancer therapy.
Jovanović M; Zhukovsky D; Podolski-Renić A; Domračeva I; Žalubovskis R; Senćanski M; Glišić S; Sharoyko V; Tennikova T; Dar'in D; Pešić M; Krasavin M
Eur J Med Chem; 2019 Nov; 181():111580. PubMed ID: 31400708
[TBL] [Abstract][Full Text] [Related]
3. Design, Synthesis, and Bioactivity Evaluations of 3-Methylenechroman-2-one Derivatives as Thioredoxin Reductase (TrxR) Inhibitors.
Nikitjuka A; Ozola M; Krims-Davis K; Žalubovskis R
ChemMedChem; 2024 Feb; 19(3):e202300504. PubMed ID: 38063319
[TBL] [Abstract][Full Text] [Related]
4. Synthesis and cytotoxic evaluation of benzoxazole/benzothiazole-2-imino-coumarin hybrids and their coumarin analogues as potential anticancer agents.
Makowska A; Wolff L; Sączewski F; Bednarski PJ; Kornicka A
Pharmazie; 2019 Nov; 74(11):648-657. PubMed ID: 31739830
[TBL] [Abstract][Full Text] [Related]
5. Further exploration of DVD-445 as a lead thioredoxin reductase (TrxR) inhibitor for cancer therapy: Optimization of potency and evaluation of anticancer potential.
Jovanović M; Zhukovsky D; Podolski-Renić A; Žalubovskis R; Dar'in D; Sharoyko V; Tennikova T; Pešić M; Krasavin M
Eur J Med Chem; 2020 Apr; 191():112119. PubMed ID: 32087464
[TBL] [Abstract][Full Text] [Related]
6. Identification of Michael acceptor-centric pharmacophores with substituents that yield strong thioredoxin reductase inhibitory character correlated to antiproliferative activity.
Gan FF; Kaminska KK; Yang H; Liew CY; Leow PC; So CL; Tu LN; Roy A; Yap CW; Kang TS; Chui WK; Chew EH
Antioxid Redox Signal; 2013 Oct; 19(11):1149-65. PubMed ID: 23311917
[TBL] [Abstract][Full Text] [Related]
7. Some new indole-coumarin hybrids; Synthesis, anticancer and Bcl-2 docking studies.
Kamath PR; Sunil D; Ajees AA; Pai KS; Das S
Bioorg Chem; 2015 Dec; 63():101-9. PubMed ID: 26469742
[TBL] [Abstract][Full Text] [Related]
8. Design, Synthesis, and In Vitro Evaluation of Novel 3, 7-Disubstituted Coumarin Derivatives as Potent Anticancer Agents.
Wang Y; Liu H; Lu P; Mao R; Xue X; Fan C; She J
Chem Biol Drug Des; 2015 Oct; 86(4):637-47. PubMed ID: 25626768
[TBL] [Abstract][Full Text] [Related]
9. Novel 3-aryl-5-substituted-coumarin analogues: Synthesis and bioactivity profile.
Kavetsou E; Katopodi A; Argyri L; Chainoglou E; Pontiki E; Hadjipavlou-Litina D; Chroni A; Detsi A
Drug Dev Res; 2020 Jun; 81(4):456-469. PubMed ID: 31943295
[TBL] [Abstract][Full Text] [Related]
10. Design and Synthesis of Novel Coumarin Conjugated Acetamides as Promising Anticancer Agents: An In Silico and In Vitro Approach.
Mamatha SV; Belagali SL; Bhat M; Kumbar VM
Anticancer Agents Med Chem; 2021; 21(11):1431-1440. PubMed ID: 32664844
[TBL] [Abstract][Full Text] [Related]
11. Synthesis and structure-activity relationship of coumarins as potent Mcl-1 inhibitors for cancer treatment.
Xia YL; Wang JJ; Li SY; Liu Y; Gonzalez FJ; Wang P; Ge GB
Bioorg Med Chem; 2021 Jan; 29():115851. PubMed ID: 33218896
[TBL] [Abstract][Full Text] [Related]
12. Coumarin-thiazole and -oxadiazole derivatives: Synthesis, bioactivity and docking studies for aldose/aldehyde reductase inhibitors.
Ibrar A; Tehseen Y; Khan I; Hameed A; Saeed A; Furtmann N; Bajorath J; Iqbal J
Bioorg Chem; 2016 Oct; 68():177-86. PubMed ID: 27544072
[TBL] [Abstract][Full Text] [Related]
13. Design, synthesis and bioactivity evaluation of coumarin-chalcone hybrids as potential anticancer agents.
Wang Y; Zhang W; Dong J; Gao J
Bioorg Chem; 2020 Jan; 95():103530. PubMed ID: 31887477
[TBL] [Abstract][Full Text] [Related]
14. Indolin-2-one compounds targeting thioredoxin reductase as potential anticancer drug leads.
Kaminska KK; Bertrand HC; Tajima H; Stafford WC; Cheng Q; Chen W; Wells G; Arner ES; Chew EH
Oncotarget; 2016 Jun; 7(26):40233-40251. PubMed ID: 27244886
[TBL] [Abstract][Full Text] [Related]
15. Design, Synthesis and Biological Evaluation of 4, 6-Coumarin Derivatives as Anti- Cancer and Apoptosis-Inducing Agents.
Yan G; Luo J; Han X; Zhang W; Pu C; Zhou M; Zhong X; Hou X; Hou MZ; Li R
Anticancer Agents Med Chem; 2021; 21(17):2351-2367. PubMed ID: 33511941
[TBL] [Abstract][Full Text] [Related]
16. Coumarin-containing hybrids and their anticancer activities.
Zhang L; Xu Z
Eur J Med Chem; 2019 Nov; 181():111587. PubMed ID: 31404864
[TBL] [Abstract][Full Text] [Related]
17. Inhibition and crosslinking of the selenoprotein thioredoxin reductase-1 by p-benzoquinone.
Shu N; Cheng Q; Arnér ESJ; Davies MJ
Redox Biol; 2020 Jan; 28():101335. PubMed ID: 31590044
[TBL] [Abstract][Full Text] [Related]
18. Current developments of coumarin-based anti-cancer agents in medicinal chemistry.
Emami S; Dadashpour S
Eur J Med Chem; 2015 Sep; 102():611-30. PubMed ID: 26318068
[TBL] [Abstract][Full Text] [Related]
19. Design, synthesis, and biological evaluation of a novel indoleamine 2,3-dioxigenase 1 (IDO1) and thioredoxin reductase (TrxR) dual inhibitor.
Fan QZ; Zhou J; Zhu YB; He LJ; Miao DD; Zhang SP; Liu XP; Zhang C
Bioorg Chem; 2020 Dec; 105():104401. PubMed ID: 33113415
[TBL] [Abstract][Full Text] [Related]
20. Luminescent alkynyl-gold(I) coumarin derivatives and their biological activity.
Arcau J; Andermark V; Aguiló E; Gandioso A; Moro A; Cetina M; Lima JC; Rissanen K; Ott I; Rodríguez L
Dalton Trans; 2014 Mar; 43(11):4426-36. PubMed ID: 24302256
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
